Drug Trial Radar · NCT00820885
A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide
Last checked: Nov 19, 2026Latest source record: May 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
95
Actual
Start
Sep 6, 2006
Primary completion
Apr 23, 2007
Study completion Apr 23, 2007
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jan 12, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Other
- Who can join
- All sexes, from 20 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study was to study the safety and tolerability of teduglutide following a once or possibly twice daily subcutaneous injection for eight consecutive days in healthy subjects. A secondary objective was to study the pharmacokinetics of teduglutide following a once or possibly twice daily injection for eight consecutive days in healthy subjects.
Conditions
- Pharmacokinetics and Safety of Elevated Doses
Interventions
teduglutideDrug
subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.
teduglutideDrug
Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
tedguglutideDrug
lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Each dose arm is safeTime frame: Within 1 week of each cohort completion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Northwest Kinetics
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.